Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with chemotherapy within its marketing authorisation for treating recurrent, persistent or metastatic cervical cancer.
Status In progress
Process STA 2018
ID number 3798

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
02 October 2020 - 30 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 June 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance